ImmunoForge announced its LMT15 Platform, a BBB shuttle based on Leptin receptor-Mediated Transcytosis (LMT), combining high brain permeability with proprietary long-acting ELP technology for once-monthly CNS-targeted therapies.1
LMT15 won first place at 'Novo Nordisk Partnering Day Korea 2026' on April 1, 2026, earning expert feedback, investment mentoring, and collaboration opportunities from Novo Nordisk and Novo Holdings.1
ImmunoForge filed a patent for LMT15 earlier in 2026 and is initiating full-scale CNS pipeline development while seeking global joint research and technology transfer.1
At Bio-Europe Spring 2026 (March 23-25, Lisbon), ImmunoForge is promoting LMT15 partnering alongside Phase 2 assets PF1801 (for PM/DM) and PF1804 (DMD cardiomyopathy, FDA IND approved).2
ImmunoForge is a clinical-stage biopharma focused on rare and muscular diseases, with $32M raised and ongoing clinical trials for PF1801 (Phase 2) and PF1804.12
Sources:
1. https://www.biospace.com/press-releases/immunoforge-to-accelerate-cns-drug-development-with-innovative-bbb-shuttle-platform-lmt15
2. https://www.prnewswire.com/news-releases/immunoforge-to-conduct-strategic-partnering-at-bio-europe-spring-2026-302712139.html